Koup RA, Merluzzi VJ, Hargrave KD, et al. Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by the dipyridodiazepinone BI-RG-587. J Infect Dis 1991 May; 163(5): 966–70.PubMedCrossRef
Montaner JSG, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine and zidovudine for HIV-infected patients — the INCAS trial. JAMA 1998 Mar 25; 279(12): 930–7.PubMedCrossRef
Floridia M, Bucciardini R, Ricciardulli D, et al. A randomized, double-blind trial on the use of a triple combination including nevirapine, a nonnucleoside reverse transcriptase HIV inhibitor, in antiretroviral-naive patients with advanced disease. J Acquir Immune Defic Syndr Hum Retrovirol 1999 Jan 1; 20(1): 11–9.PubMedCrossRef
Luzuriaga K, Bryson Y, Krogstad P, et al. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection. N Engl J Med 1997 May 8; 336(19): 1343–9.PubMedCrossRef
Murphy RL, Montaner J. Nevirapine: a review of its development, pharmacological profile and potential for clinical use. Exp Opin Invest Drugs 1996; 5(9): 1183–99.CrossRef
Luzuriaga K, Bryson Y, McSherry G, et al. Pharmacokinetics, safety and activity of nevirapine in human immunodeficiency virus type 1-infected children. J Infect Dis 1996 Oct; 174: 713–21.PubMedCrossRef
Mirochnick M. Antiretroviral pharmacology in pregnant women and their newborns. Ann N Y Acad Sci. In press.
Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994 Nov 3; 331(18): 1173–80.PubMedCrossRef
Shaffer N, Chuachoowong R, Mock PA, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Lancet 1999 Mar 6; 3539: 773–80.CrossRef
Wiktor SZ, Ekpini E, Karon JM, et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Cote d’Ivoire: a randomised trial. Lancet 1999 Mar 6; 353: 781–5.PubMedCrossRef
Dabis F, Msellati P, Meda N, et al. Six month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Cote d’Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. Lancet 1999 Mar 6; 353: 786–92.PubMedCrossRef
Guay L, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-infant transmission of HIV-1 in Kampala, Uganda — HIVNET 012 randomised trial. Lancet 1999 Sep 4; 354(9181): 795–802.PubMedCrossRef
Dorenbaum A, Sullivan JL, Bryson Y, et al. Antiretroviral use in pregnancy in PACTG 316: a phase III randomized, blinded study of single-dose intrapartum/neonatal nevirapine to reduce mother to infant HIV transmission [abstract no. 23281]. 12th World Conference on AIDS; 1998 Jun 28–Jul 3; Geneva.
Centers for Disease Control and Prevention. Public Health Service task force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. MMWR Morb Mortal Wkly Rep 1998; 47(RR-2): 1–30.
Morris A, Zorrilla C, Vajaranant M, et al. A review of protease inhibitors (PI) use in 89 pregnancies [abstract no. 686]. 6th Conference on Retroviruses and Opportunistic Infections; 1999 Jan 31–Feb 4; Chicago (IL).
Stek A, Khoury M, Kramer F, et al. Maternal and infant outcomes with highly active antiretroviral therapy during pregnancy [abstract 687]. 6th Conference on Retroviruses and Opportunistic Infections; 1999 Jan 31–Feb 4; Chicago (IL).
Lorenzi P, Masserei V, Laubereau B, et al. Safety of combined therapies in pregnancy [abstract]. 12th World AIDS Conference; 1998 Jun 28–Jul 3; Geneva.
Blanche S, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999 Sep 25; 354(9184): 1084–9.PubMedCrossRef
Shih CK, Rose JM, Hansen GL, et al. Chimeric human immunodeficiency virus type 1/type 2 reverse transcriptases display reversed sensitivity to non-nucleoside analog inhibitors. Proc Natl Acad Sci U S A 1991 Nov 1; 88(21): 9878–82.PubMedCrossRef
Merluzzi VJ, Hargrave KD, Labadia M, et al. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 1990 Dec 7; 250(4986): 1411–3.PubMedCrossRef
Smerdon SJ, Jager J, Wang J, et al. Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 1994; 26: 3911–5.CrossRef
Esnouf R, Ren J, Ross C, et al. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nat Struct Biol 1995; 2: 303–8.PubMedCrossRef
Zhang H, Dornadula G, Wu Y, et al. Kinetic analysis of intravirion reverse transcription in the blood plasma of human immunodeficiency virus type 1-infected individuals: direct assessment of resistance to reverse transcriptase inhibitors in vivo
. J Virol 1996; 70: 628–34.PubMed
Richman D, Rosenthal AS, Skoog M, et al. BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine. Antimicrob Agents Chemother 1991 Feb; 35(2): 305–8.PubMedCrossRef
Richman D, Havlir D, Corbeil J, et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol 1994 Mar; 68(3): 1660–6.PubMed
Maga G, Amacker M, Ruel N, et al. Resistance to nevirapine of HIV-1 reverse transcriptase mutants: loss of stabilizing interactions and thermodynamic or steric barriers are induced by different single amino acid substitutions. J Mol Biol 1997 Dec; 274(5): 738–47.PubMedCrossRef
Havlir DV, Eastman S, Gamst A, Richman DD. Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients. J Virol 1996 Nov; 70(11): 7894–9.PubMed
Cheeseman SH, Havlir D, McLaughlin MM, et al. Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. J Acquir Immune Defic Syndr 1995; 8(2): 141–51.
Mascolini M. Nevirapine: new drug, new class, new questions. J Int Assoc Physicians AIDS Care 1996 July; 2(7): 8–13.
Cheeseman SH, Hattox SE, McLaughlin MM, et al. Pharmacokinetics of nevirapine: initial single-rising-dose study in humans. Antimicrob Agents Chemother 1993 Feb; 37(37): 178–82.PubMedCrossRef
Lamson MJ, Sabo JP, MacGregor TR, et al. Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers. Biopharm Drug Dispos 1999; 20: 285–91.PubMedCrossRef
Lamson MJ, Cort S, Sabo JP, et al. Effects of food or antacid on the bioavailability of nevirapine 200 mg in 24 healthy volunteers [abstract no. 3003]. 11th World Conference on AIDS; 1996 Jul 7–12; Vancouver.
Lamson MJ, Cort S, Sabo JP, et al. Effects of gender on the single and multiple dose pharmacokinetics of nevirapine 200 mg/day [abstract no. 3004]. 11th World Conference on AIDS; 1996 Jul 7–12; Vancouver.
Kearney B, Price R, Sheiner L, et al. Estimation of nevirapine exposure within the cerebrospinal fluid using CSF: plasma area under the curve ratios [abstract no. 406]. 6th Conference on Retroviruses and Opportunistic Infections; 1999 Jan 31–Feb 4; Chicago (IL).
Riska P, Lamson M, MacGregor T, et al. Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab Dispos 1999; 27(8): 895–901.PubMed
Erickson DA, Mather G, Trager WF, et al. Characterization of the in vitro
biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos 1999; 27(12): 1488–95.PubMed
Havlir D, Cheeseman SH, McLaughlin M, et al. High dose nevirapine: safety, pharmacokinetics and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 1995 Mar; 171: 534–45.CrossRef
Dusek A, Hall D, Lamson M, et al. Once-daily dosing of nevirapine: a retrospective, cross-study analysis [abstract no. 12360]. 12th World Conference on AIDS; 1998 Jun 28–Jul 3; Geneva.
Taylor G, Back D, Lyall H, et al. Steady state plasma nevirapine concentrations during pregnancy [abstract no. 232]. Second Conference on Global Strategies for the Prevention of HIV Transmission from Mothers to Infant; 1999 Sep 5–6; Montreal.
Mirochnick M, Siminski S, Fenton T, et al. Pharmacokinetics of nevirapine in pregnant women and in their infants following in utero exposure [abstract no. 716]. Seventh Conference on Retroviruses and Opportunistic Infections; 2000 Jan 30–Feb 2; San Francisco.
Mirochnick M, Fenton T, Gagnier P, et al. Pharmacokinetics of nevirapine in human immunodeficiency virus type-1 infected pregnant women and their neonates. J Infect Dis 1998 Aug; 178: 368–74.PubMedCrossRef
Musoke P, Guay L, Bagenda D, et al. A phase I study of the safety and pharmacokinetics of nevirapine in HIV-1 infected pregnant Ugandan women and their neonates. AIDS 1999; 13(4): 479–86.PubMedCrossRef
Working Group on Antiretroviral Therapy and Medical management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. Available from the HIV/AIDS Treatment Information Service website: URL http://www.hivatis.org/ [accessed 2000 Aug 7].
Pollard RB, Robinson R, Dransfield K. Safety profile of nevirapine, a nonnucleoside inhibitor for the treatment of human immunodeficiency virus infection. Clin Ther 1998 Nov–Dec; 20(6): 1071–92.PubMedCrossRef
Virammune Product Monograph, version 3.0. Ridgefield (CT): Boehringer-Ingelheim International.
Sahai J, Cameron W, Salgo M, et al. Drug interaction study between saquinavir and nevirapine [abstract no. 614]. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22–26; Washington, DC.
Murphy R, Gagnier P, Lamson M, et al. Effect of nevirapine on pharmacokinetics of indinavir and ritonavir in HIV-1 patients [abstract no. 379]. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22–26; Washington, DC.
Lamson M, Gagnier P, Greguski R, et al. Effect of nevirapine (NVP) on pharmacokinetics (PK) of ritonavir (RTV) in HIV-1 patients [abstract]. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22–26; Washington, DC.
Murphy RL, Sommadossi JP, Lamson M, et al. Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1. J Infect Dis 1999 May; 179: 1116–23.PubMedCrossRef
Kaul DR, Cinti SK, Carver PL, et al. HIV protease inhibitors: advances in therapy and adverse reactions, including metabolic complications. Pharmacotherapy 1999; 19(3): 281–98.PubMedCrossRef
Department of Health and Human Services, Henry J Kaiser Foundation. Panel on Clinical Practices for Treatment on HIV Infection: guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Available from URL: http://www.hivatis.org/ [accessed 2000 Aug 7].
Gagnier P, Myers M, Lamson M, et al. Effect of nevirapine (NVP) on pharmacokinetics (PK) of indinavir (IDV) in HIV-1 patients [abstract]. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22–26; Washington, DC.
Barry M, Mulcahy F, Merry C, et al. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pharmacokinet 1999 Apr; 36(4): 289–304.PubMedCrossRef
Merry C, Barry MG, Mulcahy F, et al. The pharmacokinetics of combination therapy with nelfinavir plus nevirapine. AIDS 1998 Jul; 12(10): 1163–7.PubMedCrossRef
Skowron G, Leoung G, Kerr B, et al. Lack of pharmacokinetic interaction between nelfinavir and nevirapine. AIDS 1998; 12(10): 1243–4.PubMedCrossRef
Skowron G, Leoung G, Dusek, et al. Stavudine (d4T), nelfinavir (NFV), and nevirapine (NVP): preliminary safety, activity, and pharmacokinetic (PK) interactions [abstract no. 350]. 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1–5; Chicago (IL).
Mulcahy F, Barry M, Merry C, et al. Nelfinavir and nevirapine interaction?. AIDS 1998 Dec; 12(17): 2361.PubMed
Lal R, Hsu A, Bertz R, et al. Evaluation of the pharmacokinetics (PK) of the concurrent administration of ABT-378/ritonavir (ABT-378/r) and nevirapine (NVP) [abstract]. 7th European Conference on Clinical Aspects and Treatment of HIV-Infection; 1999 Oct 23–27; Lisbon.
Lamson M, Robinson P, Gigliotti M, et al. The pharmacokinetic interactions of nevirapine and ketoconazole [abstract]. 12th World AIDS Conference; 1998 Jun 28–Jul 3; Geneva.
Robinson P, Gigliotti M, Lamson M, et al. Effect of the reverse transcriptase inhibitor, nevirapine on the steady-state pharmacokinetics of clarithromycin in HIV-positive patients [abstract]. 6th Conference on Retroviruses and Opportunistic Infections; 1999 Jan 31–Feb 4; Chicago (IL).
Robinson P, Lamson M, Myers M. Pharmacokinetic (PK) interaction between nevirapine (NVP) and rifampin (RMP) [abstract]. 12th World AIDS Conference; 1998 Jun 28–Jul 3; Geneva.
Burman WJ, Gallicano K, Peloquin C. Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis. Clin Infect Dis 1999 Mar; 28: 419–30.PubMedCrossRef
Center for Disease Control and Prevention. Notice to readers: updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. MMWR Morb Mortal Wkly Rep 2000; 49; 185–9.
Leitz G, Mildvan D, McDonough M, et al. Nevirapine (Viramune, NVP) and ethinyl estradiol/norethindrone [Ortho-Novum 1/35 (21 pack) EE/NET] interaction study in HIV-1 infected women [abstract no. 89]. Seventh Conference on Retroviruses and Opportunistic Infections; 2000 Jan 30–Feb 2; San Francisco (CA).
Altice FL, Friedland GH, Cooney EL. Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS 1999; 13(8): 957–62.PubMedCrossRef
Otero MJ, Fuertes A, Sanchez R, et al. Nevirapine-induced withdrawal symptoms in HIV patients on methadone maintenance programme: an alert. AIDS 1999; 13(8): 1004–5.PubMedCrossRef
Gourevitch MN, Friedland GH. Methadone and antiretroviral medications, part 1. AIDS Clin Care 1999 Apr; 11(4): 30–1.PubMed
Tseng AL, Foisy MM. Significant interactions with new antiretrovirals and psychotropic drugs. Ann Pharmacother 1999 Apr; 33: 461–73.PubMedCrossRef
Cooper ER, Nugent RP, Diaz C, et al. After AIDS clinical trial 076: the changing pattern of zidovudine use during pregnancy, and the subsequent reduction in the vertical transmission of human immunodeficiency virus in a cohort of infected women and their infants. Women and Infants Transmission Study Group. J Infect Dis 1996 Dec; 174(6): 1207–11.PubMedCrossRef
Mofenson L. Short-course zidovudine for prevention of perinatal infection. Lancet 1999 Mar 6; 353: 766–7.PubMedCrossRef
Marseille E, Kahn JG, Mmiro F, et al. Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa. Lancet 1999 Sept 4; 354(9181): 803–9.PubMedCrossRef
Jackson BJ, Bedker-Pergola G, Guay L, et al. Indentification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. AIDS 2000; 14: F111–5.PubMedCrossRef
Dunn DT, Newell ML, Ades AE, et al. Risk of human immunodeficiency virus type 1 transmission through breastfeeding. Lancet 1992; 340: 585–8.PubMedCrossRef
Bobat R, Moodley D, Coutsoudis A, et al. Breastfeeding by HIV-1 infected women and outcome in their infants: a cohort study from Durban, South Africa. AIDS 1997 Nov; 11(13): 1627–33.PubMedCrossRef
Nagelkerke NJD, Moses S, Embree JE, et al. The duration of breastfeeding by HIV-1-infected mothers in developing countries: balancing benefits and risks. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 8(2): 176–81.PubMedCrossRef
Nduati R. Clinical studies of breast milk vs formula feeding [abstract no. 47]. Second Conference on Global Strategies for the Prevention of HIV Transmission from Mothers to Infant; 1999 Sep 1–6; Montreal.
European Mode of Delivery Collaboration. Elective caesareansection versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial. Lancet 1999 March 29; 353(9158): 1035–9.CrossRef
Murphy RL, Katlama C, Johnson V, et al. The Atlantic Study: a randomized open-label trial comparing two protease inhibitor (PI)-sparing antiretroviral strategies versus a standard PI-containing regimen, 48 week data [abstract]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26–29; San Francisco (CA).
Montaner JSG, Reiss P, Cooper D, et al. Aphase II, double-blind trail comparing combinations of nevirapine, didanosine, and zidovudine in HIV-infected patients. The INCAS trial. JAMA 1998; 279: 930–7.PubMedCrossRef
Luzuriaga K, Mcmanus M, Britto P, et al. Early combination antiretroviral therapy of vertical HIV-1 infection: viral kinetics and control of viral replication [abstract no. LB12]. Fifth Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1–5; Chicago (IL).